Last reviewed · How we verify
Gradual dose reduction of semaglutide
Gradual dose reduction of semaglutide is a GLP-1 receptor agonist Small molecule drug developed by Mount Sinai Hospital, Canada. It is currently in Phase 3 development for Weight management and metabolic outcomes following gradual semaglutide dose reduction, Assessment of weight rebound and glycemic control post-tapering in obese or overweight patients.
Gradual dose reduction of semaglutide investigates the effects of tapering a GLP-1 receptor agonist to assess weight maintenance, metabolic outcomes, and safety upon discontinuation.
Gradual dose reduction of semaglutide investigates the effects of tapering a GLP-1 receptor agonist to assess weight maintenance, metabolic outcomes, and safety upon discontinuation. Used for Weight management and metabolic outcomes following gradual semaglutide dose reduction, Assessment of weight rebound and glycemic control post-tapering in obese or overweight patients.
At a glance
| Generic name | Gradual dose reduction of semaglutide |
|---|---|
| Sponsor | Mount Sinai Hospital, Canada |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Obesity |
| Phase | Phase 3 |
Mechanism of action
Semaglutide is a GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, and slows gastric emptying to lower blood glucose and promote weight loss. This Phase 3 trial examines whether gradual dose reduction preserves therapeutic benefits or leads to rebound weight gain and metabolic deterioration, informing optimal long-term treatment strategies.
Approved indications
- Weight management and metabolic outcomes following gradual semaglutide dose reduction
- Assessment of weight rebound and glycemic control post-tapering in obese or overweight patients
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Weight rebound
- Hyperglycemia rebound
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gradual dose reduction of semaglutide CI brief — competitive landscape report
- Gradual dose reduction of semaglutide updates RSS · CI watch RSS
- Mount Sinai Hospital, Canada portfolio CI
Frequently asked questions about Gradual dose reduction of semaglutide
What is Gradual dose reduction of semaglutide?
How does Gradual dose reduction of semaglutide work?
What is Gradual dose reduction of semaglutide used for?
Who makes Gradual dose reduction of semaglutide?
What drug class is Gradual dose reduction of semaglutide in?
What development phase is Gradual dose reduction of semaglutide in?
What are the side effects of Gradual dose reduction of semaglutide?
What does Gradual dose reduction of semaglutide target?
Related
- Drug class: All GLP-1 receptor agonist drugs
- Target: All drugs targeting GLP-1R
- Manufacturer: Mount Sinai Hospital, Canada — full pipeline
- Therapeutic area: All drugs in Endocrinology / Obesity
- Indication: Drugs for Weight management and metabolic outcomes following gradual semaglutide dose reduction
- Indication: Drugs for Assessment of weight rebound and glycemic control post-tapering in obese or overweight patients
- Compare: Gradual dose reduction of semaglutide vs similar drugs
- Pricing: Gradual dose reduction of semaglutide cost, discount & access